Key facts
- It has raised $17.5M; the latest was Later Stage VC in Apr 2025.
- Notable investors include Tech Incubator Program for Startup, Korea Investment Partners, Schmidt (South Korea), DAYLI Partners, Korea Venture Investment — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Txinno Bioscience
- ·The full record, as it builds
Funding rounds
No funding rounds for Txinno Bioscience are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Txinno Bioscience
Developer of biotech drugs designed to discover the cure for cancer and its related issues. The company secures and builds core platform technologies such as small small-molecule innovative anti-cancer drug pipeline, innate immune anti-cancer drug evaluation technology, LIN/TMED, and kinase inhibitor evaluation technology, Ba/F3 evaluation system targets innate immunity via small-molecule compounds in immunotherapy and RAS-mutated anti-cancer drugs in targeted cancer therapy, enabling patients to get better treatments for cancer-related diseases.
- Sector
- Healthcare
- HQ
- Yongin, South Korea
- Founded
- 2020
- Employees
- 13
- Website
- txinno.com/
- Ownership
- Privately Held (backing)
Txinno Bioscience doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Txinno Bioscience shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Txinno Bioscience in its N-PORT filings yet. We sweep new filings monthly.